ReviewSeminars in interventional radiology2024
Yttrium-90 Radioembolization Dosimetry: Dose Considerations, Optimization, and Tips.
Review in Seminars in interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Predictors of Hepatic Decompensation Post-Y90 Treatment in Hepatocellular Carcinoma: New Insights into Segmental TARE and Post-Treatment Dosimetry.Journal of gastrointestinal cancer · 2026Article
- Real World Outcomes of Prescribed Ablative Dose Yttrium-90 Resin Selective Internal Radiation Therapy of Hepatocellular Carcinoma.World journal of nuclear medicine · 2026Article
- Review
- Screening the advantageous population for liver cancer undergoing yttrium-90 microsphere selective internal radiation therapy.Liver research (Beijing, China) · 2026Review
- Yttrium-90 Transarterial Radioembolization for Intrahepatic Cholangiocarcinoma: A Comprehensive Review.Journal of gastrointestinal cancer · 2026Review
- Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026Review
- Understanding Current Trends and Advances in Transarterial Radioembolization Dosimetry.Diagnostics (Basel, Switzerland) · 2025Review
- Post-Treatment PET/CT Dosimetry to Predict Contralateral Lobe Hypertrophy After Transarterial Radioembolization for Hepatocellular Carcinoma.Korean journal of radiology · 2025Article
- Transarterial Radioembolization for Hepatocellular Carcinoma in Korea: Current Clinical Practices, Facility Requirements, and Patient Selection.Journal of the Korean Society of Radiology · 2025Review
- Radioembolization: Technical Tips and Follow-Up Imaging.Journal of the Korean Society of Radiology · 2025Review
- Optimizing Yttrium-90 Radioembolization Dosimetry for Hepatocellular Carcinoma: A Korean Perspective.Korean journal of radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.